Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

類似資料

• Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
  著者:: Roberts, Patrick J., 等
  出版事項: (2012)
• CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury
  著者:: DiRocco, Derek P., 等
  出版事項: (2013)
• The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
  著者:: Paternot, Sabine, 等
  出版事項: (2014)
• Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation
  著者:: Bockstaele, Laurence, 等
  出版事項: (2009)
• CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
  著者:: Lai, Anne Y, 等
  出版事項: (2020)